Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Language
Publication year range
1.
Ginecol Obstet Mex ; 72: 135-41, 2004 Apr.
Article in Spanish | MEDLINE | ID: mdl-15318753

ABSTRACT

BACKGROUND: Ectopic pregnancy is the implantation of fertilized ovum on any tissue other than the endometrial lining of the uterus. OBJECTIVE: To evaluate the effectiveness and safeness of methotrexate in the treatment of unruptured ectopic pregnancy. MATERIALS AND METHODS: From January 2000 to October 2002 five patients were diagnosed with unruptured ectopic pregnancy in Hospital Juarez de Mexico. The inclusion criteria were: hemodynamic stability, gestational sac of < 40 mm, serum beta-hCG concentration < 15,000 mIU/L and future fertility desire. Systemic methotrexate was administered as an intramuscular injection of 50 mg. Evaluation was based on transvaginal ultrasonography, beta-hCG levels and hysterosalpingography. RESULTS: Five patients with unruptured ectopic pregnancy were treated with methotrexate. Successful rate, after one or two injections, was 100% (5 patients). The size of ectopic pregnancy as estimated by ultrasonographic was 33.33 mm. Negligible plasma beta-hCG values were reached 45.6 +/- 19.85 days after the time of treatment. Ultrasonographic scanning demonstrated progressive disorganization and the gestational sac disappeared at 134 days after treatment. There were no adverse effects from the chemotherapy. In 3 of 4 women who underwent hysterosalpingography following treatment, patency of the affected tube was observed. Three women experienced an intrauterine pregnancy spontaneously in the methotrexate group. CONCLUSIONS: Systemic methotrexate treatment is safety and effective in the treatment of unruptured ectopic pregnancy, for woman with future desire of fertility and if it has unruptured, conservative treatment using methotrexate is an excellent choice.


Subject(s)
Abortifacient Agents, Nonsteroidal/therapeutic use , Methotrexate/therapeutic use , Pregnancy, Tubal/drug therapy , Abortifacient Agents, Nonsteroidal/administration & dosage , Abortifacient Agents, Nonsteroidal/adverse effects , Adult , Chorionic Gonadotropin, beta Subunit, Human/blood , Female , Humans , Hysterosalpingography , Injections, Intramuscular , Methotrexate/administration & dosage , Methotrexate/adverse effects , Pregnancy , Pregnancy Trimester, First , Pregnancy, Tubal/blood , Pregnancy, Tubal/diagnostic imaging , Safety , Treatment Outcome , Ultrasonography
2.
Ginecol. obstet. Méx ; 68(1): 35-38, ene. 2000. tab, CD-ROM
Article in Spanish | LILACS | ID: lil-304373

ABSTRACT

Se presenta el caso de una paciente de 30 años de edad con esterilidad secundaria, opsomenorrea b de 56 días, dolor a la movilización cervical, tumoración en anexo izquierdo, sub unidad b de gonadotrofina criónica humana (GCH) de 112 mUI/mL, ultrasonido transvaginal con flujo vascular trofoblástico con actividad cardiaca compatible con gestación ectopia.La laparoscopia confirma el diagnóstico de embarazo ectópico intersticial izquierdo, realizándose salpingocentesis con metotrexato y cloruro de potasio (KCI). Como hallazgos se encuentra endometriosis severa. Durante el control postoperatorio los niveles séricos de sub unidad b de GCH sé negativizaron en 28 días; el tratamiento continuo durante cuatro meses con nafarelina. La laparoscopia histeroscopia de segunda mirada (second look) mostró resolución completa de la gestación ectópica, mejoría en 1 endometriosis y permeabilidad tubaria bilateral.


Subject(s)
Humans , Female , Pregnancy , Adult , Pregnancy, Ectopic/drug therapy , Endometriosis , Methotrexate , Nafarelin , Potassium Chloride , Infertility, Female , Laparoscopy
SELECTION OF CITATIONS
SEARCH DETAIL
...